
Investing.com -- DaVita HealthCare Partners Inc (NYSE:DVA) shares rose after UBS upgraded the operator of kidney dialysis centers, citing growth opportunities.
UBS raised its price target to Buy from Neutral, and its price target on the stock to $142 from $100. The shares are currently trading around $114.
Shares of DaVita rose 4.9% in Monday trading. They are up nearly 53% so far this year.
The analysts said in a note “we see inflecting treatment growth in 2Q-3Q ahead of accelerating growth in 2024” and beyond. “Combined with better pricing and a lower cost structure (ESA savings, closed clinics), we see numerous tailwinds.”
COVID-19 shutdowns disrupted dialysis treatment, which limited patient growth and cut into same store treatment growth in 2021 and 2022, the analysts note. But that has shifted in the past three quarters. “We have seen sequential improvement in DVA's patient base,” they commented.
The analysts see flat but inflecting treatment growth in the second and third quarters before growth starts to meaningfully accelerate in the fourth quarter and next year. “When contemplating a lower fixed cost structure, the accelerating growth provides a favorable backdrop for positive operating leverage,” they said, seeing a sustainable 16%-plus for U.S. dialysis earnings before interest and taxes margin.
Begin trading today! Create an account by completing our form
At One Financial Markets we are committed to safeguarding your privacy.
Please see our Privacy Policy for details about what information is collected from you and why it is collected. We do not sell your information or use it other than as described in the Policy.
Please note that it is in our legitimate business interest to send you certain marketing emails from time to time. However, if you would prefer not to receive these you can opt-out by ticking the box below.
Alternatively, you can use the unsubscribe link at the bottom of the Demo account confirmation email or any subsequent emails we send.
By completing the form and downloading the platform you agree with the use of your personal information as detailed in the Policy.